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ABSTRACT
The Effects of Omega-3 Polyunsaturated Fatty Acids on
AMPK Activation and Lipid Metabolism in Skeletal Muscle
Myra Woodworth-Hobbs
Intramyocellular lipid accumulation and low lipid oxidative capacity contribute to the formation
of insulin resistance, but omega-3 polyunsaturated fatty acids (n-3 PUFA) are shown to attenuate
insulin resistance caused by high levels of saturated fats. The AMP-activated protein kinase
(AMPK) promotes lipid oxidation and oxidative gene expression, highlighting its possible role in
promoting insulin sensitivity by reducing lipid content and improving oxidative capacity. This
study evaluated the effects of n-3 PUFA on the AMPK pathway and alterations to lipid content,
oxidative markers, and insulin signaling proteins in a muscle cell culture model, with the
hypothesis that n-3 PUFA would attenuate the saturated fatty acid-induced increase in
intramyocellular lipids and detriments to the AMPK pathway, oxidative markers, and insulin
signaling. The findings confirm that n-3 PUFA both attenuate saturated fatty acid-induced
increases in intramyocellular lipid content and normalize insulin signaling and oxidative
metabolic markers, though independently of the AMPK signaling pathway.
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CHAPTER 1. INTRODUCTION
1.1. Background and Significance
Emergence of the lifestyle characterized by excessive nutrient intake and low physical
activity levels has significantly contributed to the worldwide prevalence of overweight and
obesity (67). The percentage of obese adults and children in the U.S. has increased to over onethird and almost one-fifth of the population, respectively, over the past 40 years (55, 67).
Obesity is an established cause of insulin resistance (21), an early hallmark in the pathogenesis
of type 2 diabetes (37) and cardiovascular disease (46). Insulin is the primary anabolic hormone
that stimulates uptake and storage of nutrients in muscle, liver, and adipose tissue (47), and
insulin resistance is defined as disturbances in insulin signaling that result in inappropriate
responses of insulin-stimulated peripheral tissues to the actions of insulin (47) of normal or high
concentrations (43).
The condition of obesity provides constant increased lipid flux into tissues (22), and lipid
accumulation in non-adipose tissue can lead to cell dysfunction and/or death (87), termed
lipotoxicity (41, 42, 44, 51, 87). Implementation of a high fat (HF) diet is associated with
abnormally high skeletal muscle lipid accumulation (87), which is highly correlated to skeletal
muscle insulin resistance (65, 76) and is a more robust measurement of insulin resistance than
body fat percentage, body mass index, and waist-to-hip ratio (22). However, both endurancetrained athletes (67) and previously untrained individuals who have undergone an endurancetraining program (60) also display increased fasting intramyocellular lipid content similar to or
greater than levels found in individuals with type 2 diabetes but conversely possess enhanced
insulin sensitivity (42, 59, 65), a condition often termed the athlete’s paradox (42). A low ability
to oxidize accumulated fatty acids (FA) is an important contributor to formation of insulin
resistance (44), and skeletal muscle oxidative capacity may be more important in determining
insulin sensitivity than intramyocellular lipid content (67). Indeed, the athlete’s paradox (42)
distinguishes that accumulation of lipids in skeletal muscle is not harmful when adaptations in
oxidative capacity are maintained and identifies the importance of targeting metabolic treatments
toward enhancement of oxidative capacity.
Formation of insulin resistance is also partially related to the type of FA accumulated in the
cell (1, 39, 81). A chronic flux of saturated FA (SFA) are shown to have detrimental effects on

cells (94) and lead to insulin resistance (39, 52), while exposure to unsaturated FA (UFA)
prevents (1, 39, 52, 76, 77), attenuates (54), or reverses (19, 46, 64) insulin resistance and when
co-administered with SFA may prevent against detrimental metabolic effects associated with
SFA treatment alone (52). Of particular interest are the long chain omega-3 (n-3)
polyunsaturated FA (PUFA), such as docosahexaenoic acid (DHA). Supplementation of a small
amount of long chain n-3 PUFA for other FA attenuates reductions in insulin sensitivity caused
by oversupply of lipids (1, 77, 81) and sucrose (19, 46, 64) in cells (1) and metabolically normal
(11, 20, 76, 77), obese (54) and insulin resistant animals (19, 46, 64). Omega PUFAs have the
unique ability to partition FA toward oxidation (6), which identifies a possible role for the
marine n-3 PUFA to improve insulin sensitivity by promoting skeletal muscle FA oxidation and
reducing intramyocellular lipid content.
An enzyme that may participate in this mechanism is the AMP-activated protein kinase
(AMPK), which controls systemic energy expenditure, glucose homeostasis, lipid metabolism
(47), and mitochondrial biogenesis (62). AMPK is activated by phosphorylation of the
threonine-172 (Thr172) residue of its α-subunit (90) by an upstream kinase (84). The level of
phosphorylated (p-) AMPK parallels the activity of AMPK (49), thus p-AMPKThr172 is an
indicator of AMPK activity.
When activated, AMPK promotes insulin-independent glucose uptake in skeletal muscle (37,
74) and also centrally regulates fat metabolism both acutely and through long-term
transcriptional control (75). Activated AMPK phosphorylates acetyl-CoA carboxylase β at its
serine-79 residue and inactivates it (13,40, 44, 73, 87, 92, 94, 97), which removes inhibition of
carnitine palmitoyl transferase-1 and promotes fat oxidation (40, 44, 73, 87, 92, 94, 97).
Activated AMPK also phosphorylates and activates the PGC1α protein on its threonine-177 and
serine-538 residues in skeletal muscle, which activates PGC1α gene expression in a feed-forward
manner (32). Since PGC1α is a master gene that regulates mitochondrial biogenesis (89), the
expression and activity levels of the mitochondrial enzymes citrate synthase and cytochrome c
oxidase provide a method for assessment of oxidative changes downstream of AMPK activity
(57, 69, 70).
Treatments that activate AMPK are shown to improve insulin sensitivity (17, 29, 30, 44, 56,
72, 91), and the ability of AMPK to enhance fatty acid oxidation and improve oxidative capacity
identifies its possible value in controlling insulin resistance (4) through reductions in
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intramyocellular lipid content. Proper insulin signaling depends on the phosphorylation of
specific tyrosine residues of the insulin-receptor substrate proteins (IRS) 1-4 (98), and the
tyrosine phosphorylation of IRS-1 can be blocked by phosphorylation of particular IRS-1 serine
(Ser) residues, including Ser636 (53), which effectively terminates insulin signal transduction
(98). The serine cascade is activated by accumulation of intramyocellular lipid metabolites (53),
and, as such, the phosphorylation of IRS-1 on Ser636 provides a method for evaluating the
effects of FA on insulin signal transduction as a marker of skeletal muscle insulin resistance.
Long-term FA treatments have been demonstrated to inhibit AMPK (44, 49) and reduce
insulin sensitivity (44) in rodent skeletal muscle, while n-3 PUFAs are shown to attenuate
reductions in insulin sensitivity associated with nutrient oversupply (10, 46, 68, 81). However,
there has been no published research to date examining the effects of marine n-3 PUFAs on
AMPK phosphorylation in skeletal muscle cell culture, and there is limited literature (13)
examining the skeletal muscle effects in vivo. Elucidating these effects may identify roles of
marine n-3 PUFAs in improving skeletal muscle lipid homeostasis and contributing to insulin
sensitivity through dis-inhibition of the insulin signaling pathway.
1.2. Purpose and Specific Aims
AMPK has the ability to regulate cellular lipid status (75) and mechanisms involved in
oxidative metabolism (32, 40), and n-3 PUFAs promote FA oxidation over storage (6); therefore,
the purpose of this thesis is to determine if n-3 PUFAs enhance FA oxidation and reduce
intramyocellular lipid accumulation through activation of the AMPK signaling pathway. The
central hypothesis is that long-term DHA treatment of C2C12 myotubes will activate the AMPK
pathway to improve oxidative metabolism, reduce intramyocellular lipid content and enhance
insulin signaling.
Specific Aim 1. Determine the long-term effects of palmitate and DHA on AMPK and ACC
phosphorylation in cultured myotubes.
Hypothesis 1.1. Long-term palmitate treatment will lead to a reduction in the phosphorylation of
AMPKThr172 and ACCSer79 in myotubes.
Hypothesis 1.2. Long-term DHA treatment will increase the phosphorylation of AMPKThr172 and
ACCSer79 in myotubes.
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Hypothesis 1.3. Long-term DHA treatment will attenuate the palmitate-induced decrease in the
phosphorylation of AMPKThr172 and ACCSer79 in myotubes.
Specific Aim 2. Determine the long-term effects of palmitate and DHA on the oxidative capacity
of cultured myotubes by evaluating the enzyme activity of citrate synthase (CS) and the protein
expression levels of PGC1α and cytochrome c oxidase (COX) IV.
Hypothesis 2.1. Long-term palmitate treatment will decrease CS activity and reduce protein
expression of PGC1α and COXIV in myotubes.
Hypothesis 2.2. Long-term DHA treatment will increase the activity of CS enhance protein
expression of PGC1α and COXIV versus control myotubes.
Hypothesis 2.3. Long-term DHA treatment will attenuate the palmitate-induced decreases in the
activity of CS and the protein expression of PGC1α and COXIV in myotubes.
Specific Aim 3. Determine the long-term effects of palmitate and DHA on intramyocellular
lipid content of cultured myotubes and any related changes in insulin signaling as determined by
phosphorylation of the insulin receptor substrate 1 (IRS-1) on serine 636/639.
Hypothesis 3.1. Long-term palmitate treatment will increase the intramyocellular lipid content
of myotubes and the phosphorylation of IRS-1Ser636/639.
Hypothesis 3.2. Long-term DHA treatment will not change intramyocellular lipid content of
myotubes from control levels or lead to increases in phosphorylation of IRS-1Ser636/639.
Hypothesis 3.3. Long-term DHA treatment will attenuate the palmitate-induced increases in
intramyocellular lipid content and phosphorylation of IRS-1Ser636/639.
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CHAPTER 2. REVIEW OF LITERATURE
2.1. Obesity contributes to the formation of insulin resistance and other chronic diseases
Excessive nutrient intake and low physical activity levels significantly contribute to the
development of overweight and obesity. Overweight is defined as a body mass index (BMI) of
25 kg/m2-29.9 kg/m2, and obesity is defined as BMI ≥30 kg/m2 (67). In the year 2000, the
percentage of overweight and obese individuals over 20 years old in the United States was 63%
and 30%, respectively (67). Furthermore, the prevalence of individuals with extreme obesity
(BMI ≥40 kg/m2) has increased by 2.8% in men and 6.9% in women as of 2004 (55). The
prevalence of obesity in children ages 6-19 years has increased from 4% to 17.1% between 19602004 (55, 67), which is alarming because overweight children are more likely to be overweight
or obese as adults (25). Obesity and weight gain are established causes of insulin resistance and
type 2 diabetes (21), and complications accompanying type 2 diabetes are a major cause of
disability and death (72). Obesity and weight gain also increase the risk for many other
disorders, such as high blood pressure, high cholesterol, asthma, arthritis, and cardiovascular
disease (67). The developing obesity epidemic in adults, adolescents, and children across the
globe will continue to have enormous implications on healthcare and supporting research for
many years to come. To reduce the future incidence of these diseases, multiple treatment
strategies are needed that normalize metabolic control and prevent mortality-associated systemic
complications (72).
2.2. Obesity is associated with intramyocellular triglyceride accumulation and formation of
bioactive lipid species that contribute to insulin resistance
Skeletal muscle from obese humans displays an increased quantity of fatty acid (FA)
transporters in the muscle membrane (71) and increased rates of fatty acid uptake (71, 74) and
esterification (74), as well as decreased contents of cytosolic FA binding protein for intracellular
FA transport (50) and reduced rates of FA oxidation (71, 74). Together these factors lead to the
obesity-associated phenotypic characteristic of accelerated intramyocellular triglyceride
synthesis (22). Skeletal muscle from high-fat fed animals is also shown to have a higher rate of
intramyocellular triglyceride turnover than that of lean littermates, which leads to chronically
increased levels of lipid intermediates (22).
5

When a long chain FA enters the cell, it is rapidly converted to fatty acyl CoA (FACoA) by
acyl CoA synthetase (22). This conversion is a required step for entrance into several different
metabolic processes, which is dictated by the structure of the FA (34). FACoA can undergo
elongation and/or desaturation or be formed into complex lipids such as membrane
phospholipids (34). FACoA can also be converted to long chain acylcarnitine by carnitine
palmitoyl transferase-1 (CPT-1) and immediately β-oxidized by the mitochondria, or it can be
converted to the lipid intermediate diacylglycerol and then to triacylglycerol (TAG or TG) for
storage (67). When a stored TG molecule is hydrolyzed, one molecule each of diacylglycerol
and FACoA is released (22), and, as such, a chronic FA flux can lead to intracellular
accumulation of diacylglycerol and FACoA (73, 92) either directly through esterification or
indirectly through TG accumulation and subsequent hydrolysis.
Diacylglycerol, long chain FaCoA (22) and ceramides (75) are bioactive lipid signaling
molecules that can enter and interfere with non-oxidative metabolic pathways (88), leading to
lipotoxic defects such as formation of insulin resistance (22). One mechanism underlying
lipotoxic insulin resistance is through defects in the insulin signaling pathway. Binding of
insulin to its transmembrane receptor stimulates the phosphorylation of specific tyrosine residues
of numerous target proteins, including the insulin-receptor substrate proteins (IRS) 1-4, which
then associate with other downstream kinases to ultimately mediate the metabolic and growthpromoting functions of insulin (98). However, the tyrosine phosphorylation of IRS-1 can be
blocked by phosphorylation of particular IRS-1 serine (Ser) residues, including Ser636 (53) and
Ser1101, the latter of which has been associated with IRS-1 degredation (33). Serine
phosphorylation of IRS-1 uncouples the protein from its upstream and downstream effectors and
terminates signal transduction from insulin (98). It has been demonstrated that the serine
cascade is activated by accumulation of intramyocellular lipid metabolites (53). Therefore, the
phosphorylation of IRS-1 on Ser636 and Ser1101 provides a method for evaluating the effects of
FA on insulin signal transduction as a marker of skeletal muscle insulin resistance.
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2.3. AMPK is a master metabolic regulator
2.3.1. AMPK is important in systemic metabolism
The adenosine monophosphate-activated protein kinase (AMPK) pathway is a possible target
for treatment of insulin resistance (4). AMPK is a conserved cellular energy gauge (51, 90, 94)
that serves as a master metabolic regulator by controlling systemic energy expenditure, food
intake, glucose homeostasis, and lipid metabolism (47). The protein kinase is activated in
conditions of energy depletion (17, 40) or metabolic stress (28), such as muscle contraction (17,
37), exercise (17, 56), and hypoxia (37), and can also be stimulated pharmacologically (44, 56,
91). Activation of AMPK acts to conserve cellular energy stores (47, 73) by acutely suppressing
energy-consuming pathways, such as synthesis of glycogen, cholesterol, and lipids (73), and
inducing energy-producing pathways, such as glucose uptake (94) and FA oxidation (92, 94).
AMPK is an important regulator of insulin-independent glucose uptake into tissues by promoting
glucose transporter 4 (GluT4) translocation to the sarcolemma (37), as well as increased
expression (47), phosphorylation, and activation (74) of transcription factors regulating the
GluT4 gene promoter. Also of particular interest is the ability of AMPK to sense the lipid status
of a cell (90, 94), independent of cellular energy charge (92).
7

2.3.2. Enzymatic characteristics of AMPK
AMPK is a heterotrimeric enzyme formed by α, β, and γ subunits (47, 84, 94). Each subunit
has multiple isoforms encoded by separate genes: α1, α2, β1, β2, γ1, γ2, and γ3 (75). AMPK is
ubiquitously expressed in mammalian tissues, though some tissue-specific expression is
observed with the β and γ subunits and the contribution of each α isoform to total AMPK activity
(4). Skeletal muscle AMPK complexes mostly contain α2/β2, 80% of which are associated with
γ1 (73), though glycolytic skeletal muscle predominately contains α2/β2/γ3 complexes (4).
The α subunit provides the catalytic activity of AMPK (75, 94) and contributes to AMP
binding (4). In skeletal muscle, the α1 subunit is predominately cytoplasmic (84), while the α2
subunit is located in the cytoplasm and nucleus, and cytoplasmic α2 translocates to the nucleus
upon stimulation (80), indicating its participation in regulation of gene expression. The
regulatory β subunit serves as a docking area for α and γ subunits and also contains a glycogen
binding domain (75), suggesting a possible role in glycogen feedback regulation of AMPK (4).
Additionally, the β subunit is important for determining the localization of the α subunit; in
C2C12 skeletal muscle cells, β2 is shown to aide in the nuclear localization of α2, while β1
contributes to the return of α2 to the cytoplasm after stimulation (80). The γ subunit is
responsible for binding AMP or ATP and thus provides for allosteric control of AMPK (75). It
also stabilizes the α subunit and is essential for the catalytic activity of AMPK (4). The γ1 and
γ2-isoforms are widely distributed throughout tissues, while the γ3-isoform is highly specific for
glycolytic skeletal muscle where it plays a role in regulation of carbohydrate metabolism (4) but
not lipid oxidation (3). The γ1 isoform is the only γ subunit expressed in C2C12 cells and is
required for both phosphorylation and nuclear translocation of α2 (80).
2.3.3. Allosteric modulation and phosphorylation of AMPK
Multiple mechanisms contribute to regulation of the AMPK pathway, which varies between
tissues (47). AMPK can be regulated through both allosteric modulation and phosphorylation.
Allosteric activation of AMPK due to increasing concentrations of cellular AMP (94) leads to a
5-fold increase (84) in the enzymatic activity of AMPK. AMPK can also be allosterically
inhibited by the presence of physiological concentrations of phosphocreatine (13, 24) and
adenosine triphosphate (ATP) (73). Importantly, allosteric binding of AMP also both facilitates
the phosphorylation of AMPK on the threonine-172 (Thr172) residue in the activation loop of
8

the α-subunit (90) by an upstream kinase and reduces the inhibitory dephosphorylation of
AMPKThr172 by its upstream phosphatases (84). Phosphorylation of AMPK results in a 100-fold
increase in AMPK activity (23, 84), and when combined with allosteric modulation produces
greater than 1000-fold activation of AMPK (23). Since the level of phosphorylated (p-) AMPK
parallels the activity of AMPK (49), p-AMPKThr172 is commonly used to indicate AMPK
activity. Furthermore, phosphorylation of AMPK on its Ser485/491 residues has been associated
with a decrease in phosphorylation of AMPKThr172 (27), indicating its usefulness as a measure of
AMPK inactivation.
The primary upstream kinase activating AMPK is the tumour suppressor kinase (LKB1) (73,
75, 84), which phosphorylates AMPKαThr172 in response to increasing AMP concentrations (84).
The calcium/calmodulin-dependent protein kinase kinase (CaMKK) shows significant homology
to LKB1 and has also been identified as an AMPK-activator (28). CaMKK is activated by
increasing intracellular calcium levels and regulates AMPK independently of the AMP/ATP
ratio (47). The primary upstream phosphatases to AMPK are the protein phosphatases (PP) 2C
(73) and 2A (74). Adipose tissue also exerts effects on skeletal muscle fuel metabolism, as the
adipokines adiponectin and leptin have been identified as AMPK-activators (51, 96). Leptin is
adipocyte-derived protein hormone secreted in proportion to fat storage content (49) that helps
regulate energy flow (35). Leptin has been shown to decrease peripheral TG storage and
improve insulin sensitivity (47) through improvement of FA oxidation in skeletal muscle cells
(51, 80). Adiponectin is a protein also secreted exclusively by adipocytes (64). Decreased
expression of adiponectin correlates with insulin resistance, and treatments that stimulate
production of adiponectin are associated with enhanced insulin sensitivity (64). Both leptin and
adiponectin stimulate FA oxidation in skeletal muscle through phosphorylation of AMPKα (96),
which depends on translocation of the α2 subunit from the cytoplasm to the nucleus (80).
2.3.4. AMPK contributes to acute and chronic lipid homeostasis
AMPK is a central regulator of fat metabolism both acutely and through long-term
transcriptional control (75). Classically, AMPK promotes FA oxidation by phosphorylating and
inactivating acetyl-CoA carboxylase β (ACCβ), the rate-limiting enzyme of malonyl-CoA
synthesis (40, 44, 73, 87, 92, 94, 97). The phosphorylation of ACCβ at its serine-79 (Ser79)
residue is accomplished almost exclusively by AMPK (13), thus p-ACCSer79 is an excellent
9

downstream marker for secondary measurement of AMPK activity. AMPK also phosphorylates
and activates malonyl-CoA decarboxylase (MCD), which degrades malonyl-CoA. Malonyl acts
as a powerful allosteric inhibitor of CPT-1, which shuttles FACoAs into the mitochondria for βoxidation. The effects of AMPK on ACC and MCD cause a reduction in the level of malonylCoA, subsequently disinhibiting CPT-1 and promoting fat translocation and oxidation (40, 44,
73, 87, 92, 94, 97).
AMPK also regulates long-term lipid metabolism and mitochondrial biogenesis by increasing
expression of genes involved in FA metabolism (40) and mitochondrial proteins involved in
oxidation (62). AMPK is shown to increase FA oxidation in myotubes in a dose-dependent
manner (40), which occurs with an increase in mRNA expression of the peroxisome-proliferatoractivated receptor (PPAR) γ co-activator 1α (PGC1α) (40) but not PGC1β (32). PGC1α is a
master gene that regulates mitochondrial biogenesis (89) and co-activates the PPARα to regulate
transcriptional control of FA oxidation (40). AMPK directly phosphorylates and activates the
PGC1α protein on its threonine-177 and serine-538 residues in skeletal muscle, which activates
PGC1α gene expression in a feed-forward manner (32). AMPK activation promotes expression
of the mitochondrial gene cytochrome c and increases total mitochondrial respiration, which is
dependent upon the presence of PGC1α (32). This indicates that activation of AMPK can
enhance oxidative capacity by improving mitochondrial biogenesis via PGC1α. AMPK also
increases mRNA expression of PPARα and its target genes CPT-1 and fatty acid binding protein
3 (FABP3) in myotubes and rodent skeletal muscle (40), which indicates its ability to facilitate
FA oxidation.
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2.3.5. Oxidative capacity is decreased with insulin resistance
Reductions in mitochondrial density and activity contribute to reduced oxidative capacity and
dysregulated lipid metabolism (62) and aide in the development of skeletal muscle insulin
resistance (47). A common method for assessment of oxidative capacity is measurement of
expression and activity levels of the mitochondrial enzymes citrate synthase (CS) and
cytochrome c oxidase (COX), which are shown to increase in response to aerobic exercise
training in metabolically normal animals (69, 70) and in insulin resistant humans (57) and are
decreased in conditions of insulin resistance. Insulin resistant offspring of individuals with type
2 diabetes have been shown to exhibit a trend toward lower baseline COX and CS activity levels
(57), as well as possess 38% lower mitochondrial density and 50% lower expression of COX
versus insulin-sensitive individuals, which is associated with 60% greater intramyocellular lipid
content (53). Maximal COX activity was also reduced by almost 50% after 6 weeks of high-fat
and high-sucrose feeding of male Wistar rats versus control animals (5).
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2.3.6. Activation of AMPK enhances oxidative capacity
The ability of AMPK to reduce skeletal muscle TG content by stimulating FA oxidation (44,
47) and enhancing lipid oxidative capacity (4) is important in its distinction as a positive
regulator of insulin sensitivity (44, 47). The compounds 5-aminoimidazole-4-carboxamide
ribonucleoside (AICAR) (91) and metformin (44) are pharmacological stimulators of AMPK.
AICAR potently activates AMPK (91) in cells upon formation of the adenosine analogue ZMP
(40, 47), while AMPK is an indirect target of metformin (32). While it is possible that AICAR
may also affect other AMP-sensitive enzymes, it is commonly used to examine the effects of
AMPK activation on cellular processes (9, 17, 29, 30, 37, 56, 61, 62). AICAR is shown to
increase skeletal muscle FA oxidation (32, 40) and PPARα (40), PGC1α (32, 40), CPT-1, and
FABP3 mRNA expression (40), and both AICAR and metformin increase the mRNA expression
of cytochrome c and uncoupling proteins-2 and -3 (32) in skeletal muscle cells.
Treatment of male Sprague-Dawley rats with AICAR for 4 weeks significantly increased
cytochrome c protein content in white quadriceps as well as the activity of CS, succinate
dehydrogenase, and malate dehydrogenase in white quadriceps and soleus muscles (93).
Furthermore, administration of oral metformin for 14 days to male Wistar rats increased PGC1α
protein content and CS activity in soleus and red and white gastrocnemius muscles, as well as
cytochrome c protein content in the soleus (79). These studies examining the effects of AICAR
and metformin on AMPK activity and subsequent FA oxidation and mitochondrial oxidative
capacity identify the possible value of AMPK-activating treatments in controlling insulin
resistance (4) through changes in lipid homeostasis.
2.4. Fatty acid treatments alter skeletal muscle AMPK
FA treatments have been shown to both activate (78, 92, 94) and repress (44, 83) AMPK
phosphorylation and activity, but the outcome is dependent upon the type of FA and the length of
treatment. The saturated fatty acid (SFA) palmitate comprises between 30-40% of FA in the
plasma (94) and is commonly used (7, 8, 14-16, 18, 29, 31, 39, 41, 52, 56, 59, 63, 65, 83, 85, 90,
92, 94) along with the monounsaturated fatty acid (MUFA) oleate (1, 7, 8, 18, 39, 41, 52, 59, 65,
92, 94) and omega-6 (n-6) polyunsaturated fatty acid (PUFA) linoleate (39, 92) to study the
effects of different FAs on metabolic markers. Acute palmitate (10, 76) and linoleate (76)
treatments have been shown to promote skeletal muscle AMPK and ACC phosphorylation (15,
12

92), while chronic treatment with palmitate (94) and palmitoyl-CoA (83), as well as long-term
high-fat (HF) feeding with primarily SFA (44, 49), have been shown to repress AMPK in
skeletal muscle and other cell types.
2.4.1. Acute fatty acid treatments stimulate AMPK activity
Treatment of L6 myotubes for 1 hour with 0.25 mM of SFA palmitate or PUFA linoleate
significantly increased AMPK activity, phosphorylated (p-) AMPKThr172, and p-ACCβSer218 with
no changes in cellular energy charge. Both palmitate and linoleate pre-treatments increased
subsequent palmitate oxidation rates (92). In a similar study, L6 myotubes incubated for 1 hour
with 0.001-0.8 mM palmitate demonstrated a dose-response increase in p-AMPKαThr172 and pACCSer79 levels, which was significant with as little as 0.01 mM palmitate and peaked with 0.4
mM palmitate at 3.5-fold for AMPK and 4.5-fold for ACC. Furthermore, as palmitate
concentration increased so did its oxidation (15). Similar effects are also observed in a different
cell type, as acute treatment of bovine arterial endothelial cells (BAECs) with palmitate resulted
in increased p-AMPK and p-ACC versus control-treated cells (94). Together these data indicate
that acute treatment with FA leads to activation of AMPK and inactivation of ACC to promote
FA oxidation, which supports an acute feed-forward mechanism where increased lipid
availability enhances FA oxidation to allow non-adipose cells to adapt to increasing FA flux
without initially changing lipid storage capacity.
2.4.2. Long-term fatty acid treatments repress basal AMPK activity but may not affect
the ability of AMPK to be chronically activated
More applicable to the condition of obesity is long-term FA treatment that increases cellular
and tissue lipid concentrations and detrimentally affects metabolic pathways. For example,
although palmitate treatment led to an initial activation of p-AMPK and p-ACC levels in
BAECs, these values returned to basal levels by 5 hours, and both basal and AICAR-stimulated
p-AMPK and p-ACC were significantly decreased with long-term treatment for 40 hours, which
was not due to increased ATP from palmitate oxidation or reduced AMPK or ACC expression
(94). This clearly identifies the opposing effects of FA on AMPK and ACC phosphorylation in
acute versus chronic conditions and distinguishes that the same effects may occur in skeletal
muscle.
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Indeed, animal HF feeding studies mimic the Western diet of nutrient oversupply and have
been shown to inhibit AMPK in rodent skeletal muscle (44, 49). Male Wistar rats fed a 22% fat
diet of predominately lard for 5 months demonstrated significant decreases in basal total- and
phosphorylated-AMPKα protein, AMPKα2 mRNA, and p-ACC protein versus chow-fed animals
in the gastrocnemius muscle, which was associated with decreased basal and insulin-stimulated
glucose uptake during hyperinsulinemic clamping. However, animals receiving oral metformin
during the last month of feeding displayed an attenuation of insulin resistance as evidenced by
significant increases in the glucose infusion rate (GIR) during clamping, which was associated
with 162% and 39% increases in basal p-AMPKαThr172 and p-ACC levels, respectively (44).
This data suggests that although basal AMPK activity and expression is decreased in skeletal
muscle of HF-fed animals, they maintain the capacity to improve these levels through chronic
pharmacological activation, which is also associated with enhanced insulin sensitivity.
Young male FVB mice fed a 55% fat diet of predominately lard for 5-12 weeks showed
impaired AMPK phosphorylation and activity in response to leptin administration in the soleus
muscle but demonstrated unimpaired AMPK activation by AICAR (49), identifying that these
animals were leptin resistant but still maintained the ability to sense cellular energy charge.
Furthermore, another group (36) reported that 3-week old male Wistar rats fed a 50% fat diet for
4 weeks were insulin resistant but did not display significantly different hypoxia-stimulated pAMPK levels than chow-fed animals. These studies suggest that HF-feeding does not affect the
ability of skeletal muscle AMPK to become activated by agents other than leptin, indicating that
these pathways may be targeted to induce positive metabolic effects. However, feeding studies
of over 14 weeks are considered long-term in rats (46); therefore, further studies are needed to
identify the ability of skeletal muscle AMPK to be activated after chronic HF-feeding. Chronic
SFA treatment of BAECs led to reduced basal and AICAR-activated AMPK levels (94),
highlighting the need for these studies in skeletal muscle.
Together these data suggest that short-term HF feeding does not alter the ability of AMPK to
be activated and leads to adaptations in FA oxidation to meet cellular needs, while long-term HFfeeding leads to decreased basal AMPK activity and overcomes the adaptive capacity of the
muscle for FA oxidation when unaided by pharmacological activators or stress-inducing
conditions. These studies did not examine the effects of PUFA supplementation on basal and
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stimulated p-AMPK levels, which may identify cellular role(s) of PUFAs in metabolic regulation
of lipid metabolism through alteration of skeletal muscle AMPK activity.
2.5. Cellular effects of fatty acids depend on their structures
2.5.1. Saturated and unsaturated fatty acids differentially affect cellular metabolism
The effects of dietary FA on health depend not only on the quantity but also on the nature of
the fatty acids (48). A chronic flux of SFA is demonstrated to have detrimental metabolic effects
in cells (52, 65, 94) and skeletal muscle (39) and is associated with formation of insulin
resistance (39, 52), while exposure to unsaturated fatty acids (UFA) prevents (1) (11, 39, 52, 76,
77), attenuates (54), or reverses insulin resistance (19, 46, 64). Interestingly, there is also
evidence that UFA co-administered with SFA offers prevention against detrimental metabolic
effects associated with SFA treatment alone, improving lipid homeostasis (7) and promoting
insulin sensitivity (52).
Myotubes incubated with palmitate showed increased accumulation of diacylglycerol and
formation of insulin resistance, while cells incubated with oleate had increased TG levels and no
changes in insulin sensitivity. Co-incubation of palmitate + oleate also led to increased TG
content and prevented insulin resistance in a dose-dependent manner. Furthermore, palmitate
treatment led to a reduction in PGC1α mRNA expression, while cells treated with oleate alone
and palmitate + oleate had PGC1α expression levels similar to control values and actually
demonstrated an approximate 7-fold increase in CPT-1 mRNA expression (7). This data
indicates that SFA treatment induces insulin resistance and downregulates the expression of the
mitochondrial regulator PGC1α, while UFA treatment leads to maintenance of mitochondrial
biogenesis and improvement in FA oxidation capacity and can actually prevent detrimental
effects of SFA on these parameters.
2.5.2. Omega-3 polyunsaturated fatty acids enhance insulin sensitivity
In addition to the positive effects of the MUFA oleate on prevention of insulin resistance, a
great deal of literature has examined the metabolic effects of PUFAs. The n-6 PUFA linoleic
acid and the omega-3 (n-3) PUFA linolenic acid are considered essential fatty acids because they
cannot be synthesized by mammals and must be consumed from dietary sources (66).
Metabolism of linolenic acid gives rise to two other FA (12) of particular interest in regards to
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insulin resistance, the long chain n-3 PUFAs eicosapentaenoic acid (EPA; C20:5 n-3) and
docosahexaenoic acid (DHA; C22:6 n-3). EPA and DHA are primarily found in fish, shellfish,
and sea mammals and are sparse or absent in plants and land animals (45), and at least 30
marketed species of Mediterranean fish and shellfish provide significant sources of n-3 PUFAs
by containing high levels of EPA and DHA (58). In the literature these PUFAs are often
administered in the form of fish oil (FO) (20). Conversely, n-6 PUFAs are found in foods of
animal origin and in vegetable oils (66). Currently more than 85% of the total dietary PUFA
intake in Western diets is of the n-6 moiety, while consumption of n-3 PUFAs has declined (48).
This may be one contributor to the rise in obesity-associated disease, as high intake of n-6
PUFAs has been associated with childhood obesity (48) and may lead to hyperinsulinaemia and
insulin resistance in adults (95).
In 1987, Storlein et al. (77) demonstrated that substituting a small amount of n-3 PUFAs in
the form of FO for n-6 PUFAs in a HF diet attenuated reductions in insulin sensitivity observed
with a HF-diet alone. Since this discovery, a plethora of research has been aimed at identifying
the mechanisms underlying these beneficial effects. Although it has been demonstrated that n-3
PUFA improve components of the insulin-signaling pathway in skeletal muscle (20, 38, 81),
their effects outside of the insulin-signaling pathway remain unclear. PUFAs have the unique
ability to partition FA toward oxidation (6), which identifies a possible role for the marine n-3
PUFAs to improve skeletal muscle insulin sensitivity by promoting FA oxidation and reducing
of intramyocellular lipid content. Therefore, focus will be maintained on studies identifying
effects of n-3 PUFAs on blood and skeletal muscle lipid parameters to assess possible changes in
FA flux, lipid synthesis, and oxidative metabolism as they relate to alterations in insulin
sensitivity. Little research is available on the effects of n-3 PUFAs on skeletal muscle oxidative
capacity, though one study did report that male Wistar rats fed a HF diet containing 10% n-3
PUFA + 18% SFA exhibited 48% and 83% increases in skeletal muscle acyl-CoA oxidase
activity and mRNA expression, respectively, versus rats fed a HF diet containing 28% SFA.
This was associated with a normalization of the GIR during hyperinsulinemic clamping,
indicating an enhancement of systemic insulin sensitivity (86).
Aside from direct measurements of FA oxidation and mitochondrial proteins and enzymatic
activities, changes in intramyocellular lipid contents are indicators of the possible effects of n-3
PUFAs on fatty acid metabolism in skeletal muscle. Male Wistar rats were fed a control diet
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(CON), a 70% fat diet (HF), or a HF diet with either 10% replacement of SFA with n-3 PUFAs
from FO (HF+FO) or 18.5% replacement of SFA with the n-6 PUFA gamma-linolenic acid from
borage oil (HF+GLA) for 3 weeks. The HF diet led to increased fasting insulin levels and postprandial free FA, TG, and glycerol levels, which were normalized by FO but not GLA
supplementation. Interestingly, the plasma TG levels in the HF+FO group were even
significantly lower than the control group by about 50%. The GIR during hyperinsulinemic
clamping was about 60% lower in HF versus control animals and was significantly increased
with FO supplementation. Skeletal muscle TG contents were similar in control and HF+FO
groups and were significantly lower than in animals fed HF or HF+GLA diets (68). These data
clearly indicate the hypolipidemic effect of n-3 PUFAs in blood and skeletal muscle and its
association with improved systemic insulin sensitivity.
Other studies have also assessed the effectiveness of n-3 PUFA supplementation in
prevention of insulin resistance. Male Wistar rats were fed diets containing 18.5% fat, composed
of either 8% corn oil (control diet, CD) or 1% corn oil + 7% cod liver oil (CD+CLO) for 1
month. CLO is high in the n-3 PUFAs EPA and DHA (82). The CD+CLO group exhibited
significantly lower plasma TG and insulin levels and significantly higher GIR during
euglycemic-hyperinsulinemic clamping compared to CD-fed animals (11), demonstrating an
association between short-term CLO supplementation and prevention of insulin resistance in
metabolically normal rats through improvements in systemic glucose utilization and reductions
in plasma TG levels.
Since CLO supplementation prevented fat-induced insulin resistance in normal animals, the
same group (46) evaluated the possibility that CLO supplementation could reverse diet-induced
insulin resistance. Young male Wistar rats were fed a sucrose-rich diet (SRD, 8% corn oil) for 6
months to induce dyslipidemia and insulin resistance, after which the animals were split into 2
groups and fed for 2 more months with either the same SRD or one where the 8% corn oil was
replaced by 1% corn oil + 7% CLO (SRD+CLO). CLO supplementation restored gastrocnemius
TG content to control levels and significantly reduced diacylglycerol and FACoA content versus
SRD-feeding (46), suggesting either improvement in FA oxidation or reduction in TG synthesis.
Additionally, the SRD was associated with increased fasting plasma TG, FFA, and glucose
concentrations and led to over 50% reduction in GIR during clamping versus the CD, while CLO
supplementation elicited values similar to CD-fed animals (46). These studies indicate that CLO
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supplementation is associated with normalization of skeletal muscle lipid content and improved
glucose homeostasis during fasting and insulin-stimulated conditions.
Mustad et al. (54) expanded the literature by examining the possibility of different n-3 PUFA
supplements (α-linolenic acid [ALA], EPA, or DHA) to improve glucose metabolism and insulin
sensitivity in HF-fed ob/ob mice. Mice were fed MUFA-rich diets [43-45% fat, 37-39% CHO,
and 18% protein] with n-3 PUFA percentages of either 1.2% (MUFA), 24.6% (ALA), 36.6%
(EPA), or 34.7% (DHA) for 4 weeks. EPA and DHA groups had lower plasma TG and free FA
levels than the MUFA group, which is similar to other findings (19, 46). The plasma glucose
concentration 2 hours post-meal was also significantly reduced by 40-50% in all n-3 PUFA
groups compared to MUFA-fed mice, indicating improved glucose utilization in response to
feeding (54) which may have occurred through activation of the AMPK pathway.
2.6. Polyunsaturated fatty acids may alter skeletal muscle AMPK to improve insulin sensitivity
It is clearly established that treatment with n-3 PUFAs exerts positive effects on insulin
sensitivity in skeletal muscle (1, 11, 19, 26, 46, 54, 76, 77), which has been shown in cell culture
(1), in metabolically normal (11, 76, 77), obese (54), and insulin resistant (19, 46, 64) animals,
and in humans (26). In several cases this improvement is associated with reduced plasma and
intramyocellular lipid levels (11, 46, 54, 68, 86), indicating reduced lipid flux to tissues and
either reduced TG synthesis or increased FA oxidation. AMPK-activating treatments are also
established to improve glucose and lipid homeostasis and enhance insulin sensitivity (17, 29, 30,
44, 56, 72). However, there is limited literature examining the cellular effects of marine n-3
PUFAs on AMPK, especially in skeletal muscle. AMPK is an important sensor of cellular lipid
status (90, 94) and regulator of FA oxidative metabolism (47, 92, 94) and mitochondrial
biogenesis (62). Furthermore, omega PUFAs have been identified to partition FA from storage
toward oxidation in liver and skeletal muscle (6). Therefore, it is possible that marine n-3
PUFAs exert positive effects on AMPK phosphorylation, which leads to improvements in FA
oxidation and possibly mitochondrial oxidative capacity to reduce intramyocellular lipid storage.
There has been no published research to date examining the effects of marine n-3 PUFAs on pAMPK in skeletal muscle cell culture, although the outcomes of other FA treatments on AMPK
activity have been examined (15, 92). Furthermore, only two in vivo studies have examined the

18

effects of marine n-3 PUFAs on AMPK, with one in liver (78) and the other in skeletal muscle
(13).
Male Sprague-Dawley rats were fed an initial 7-day high-glucose, no fat diet, which
decreased liver p-AMPKThr172 levels and AMPK activity by 80% and approximately 50%,
respectively, versus pre-meal values, with similar reductions in p-ACC levels and no change in
total AMPK protein concentration. This is not unexpected, as the same group demonstrated a
depression in AMPK phosphorylation and activity with re-feeding a high-carbohydrate diet after
fasting (2). For the next 7 days, rats were fed the same high-glucose diet but supplemented with
10 grams of either MUFA [triolein, 99% omega-9] or PUFA [35% EPA and DHA] per 100
grams of diet. Fasted p-AMPKαThr172 values were unchanged, while p-AMPKThr172 and pACCβSer79 levels were reduced with both diets 2 hours following the final meal. However, this
reduction was greater with the MUFA diet than the PUFA diet, as both postprandial PUFA pAMPKThr172 and p-ACC levels were approximately double MUFA levels. Furthermore, MUFA
feeding was associated with significantly lower AMPK activity levels than PUFA feeding (78).
This indicates that although AMPK was not affected in the post-absorptive state, n-3 PUFAs did
exert a greater activating effect on AMPK and ACC phosphorylation and AMPK activity than
MUFAs. Moreover, the PUFA group demonstrated lower postprandial levels of fatty acid
synthase (FAS) mRNA and higher CPT-1 mRNA expression than the MUFA group (78),
indicating a greater shift from lipogenesis toward FA oxidation with n-3 PUFA feeding.
While any FA treatment could be expected to upregulate levels of AMPK activity,
phosphorylated AMPK and ACC, FA transport proteins, and oxidative enzymes after a highglucose, no-fat diet, merely due to their renewed presence in the tissues, an n-3 PUFA treatment
was more effective than a MUFA treatment in doing so. This is promising because it suggests
that mechanism(s) other than simply the law of mass action contribute to the ability of n-3
PUFAs to activate AMPK and ACC. Whether they may do this directly by acting on AMPK or
indirectly by acting on upstream AMPK regulators still needs to be determined. Furthermore,
this study is considered short-term (46) because the MUFA and PUFA supplements were
administered for only one week, and it would be interesting to observe the chronic effects of n-3
PUFA feeding on AMPK activity, especially in relation to any alterations in systemic insulin
sensitivity.
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In response to this study, Dobrzyn et al. (13) evaluated the effects of feeding a 5% fat diet of
either PUFA from FO or MUFA from triolein for 14 days on AMPK activity in heart, liver, and
skeletal muscle of mice. They found no changes in p-AMPKThr172 levels in FO-fed animals
versus control in any tissue (13). While these results suggest that PUFAs do not activate AMPK
in mouse tissues, no changes were observed in liver p-AMPKThr172, which is contradictory to the
previous findings (78) that n-3 PUFAs are more effective in stimulating liver AMPK than
MUFAs and indicates that confounding factors may be present. For one, these animals were
metabolically challenged with stearoyl-CoA desaturase 1-deficiency, making the results difficult
to compare to other studies in metabolically normal animals. Additionally, this PUFA diet
contained 5% fat with 25% EPA/DHA content, versus 10% fat and 35% EPA/DHA content in
the study by Suchankova et al. (78), indicating that the n-3 PUFA composition of the diet may
not have been great enough to observe positive effects on AMPK activity.
HF-feeding was shown to reduce skeletal muscle AMPK phosphorylation and activity, which
correlated with reductions in systemic insulin sensitivity (44). Additionally, administration of
marine n-3 PUFAs attenuated reductions in p-AMPK, p-ACC, and CPT-1 mRNA and increased
suppression of FAS in the liver of normal animals (78). These data prompt further investigation
of the effects of marine n-3 PUFAs on skeletal muscle AMPK phosphorylation and activity to
identify if the improvement in insulin sensitivity observed with n-3 supplementation is at all
related to improvement in FA oxidation and reduction in intramyocellular lipid content.
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CHAPTER 3. RESEARCH METHODS

Materials. Mouse C2C12 myoblasts were purchased from American Type Culture Collection.
Fetal calf serum (FCS) was purchased from Atlas Biologicals. ITS Liquid Media Supplement,
palmitic acid sodium salt, cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid (DHA) oil, insulin,
Ponceau S red, 99% triethyl phosphate, and a citrate synthase assay kit (Cat# CS0720) were
purchased from Sigma. BSA was purchased from Santa Cruz Biotechnology. SDS-PAGE precast gels were purchased from Invitrogen, and nitrocellulose membranes and an RC DC protein
assay kit (#500-0121) were purchased from BioRad. Antibodies were purchased from Cell
Signaling Technology, and goat anti-rabbit and goat anti-mouse horseradish peroxidaseconjugated IgG were purchased from Jackson ImmunoResearch Laboratories, Inc.. Enhanced
chemiluminescence (ECL) was purchased from Pierce, and advanced ECL was purchased from
Amersham Biosciences. ReBlot Plus Strong Solution was purchased from Millipore. X-ray film
was purchased from Phenix Research Products. Oil Red O powder was purchased from Fluka
Analytical.
Cell culture. Mouse C2C12 myoblasts were seeded in six-well (35-mm) plates in DMEM (4.5 g/L
D-glucose, with L-glutamine, pyridoxine hydrochloride, 110 mg/L sodium pyruvate, and 3.7 g/L
sodium bicarbonate) supplemented with 10% FCS and 1% penicillin and streptomycin (PS) and
maintained in a humidified incubator at 37ºC in an atmosphere of 5% CO2. Cells were grown to
~95% confluence and then induced to differentiate into myotubes by incubation in serum- and
PS-free DMEM supplemented with 1% ITS Liquid Media Supplement for 3 days. After
differentiation, cells were maintained in DMEM with 2% FCS until experimental treatment.
Palmitate and cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid (DHA) oil were dissolved in
ethanol and diluted in DMEM containing 2% BSA to reach desired fatty acid (FA)
concentrations. For dose-response experiments, myotubes were treated separately with palmitate
and DHA in 0mM, 0.1mM, 0.25mM, 0.5mM, 0.75mM, and 1.0mM concentrations in media
containing 2% FCS, and 2% BSA for 24 hours. For time-response experiments, myotubes were
treated with media containing 2% FCS, 2% BSA, and 0.5mM palmitate or 0.1mM DHA for 24,
48, and 96 hours. For all subsequent experiments, myotubes were treated with media containing
2% FCS, 2% BSA, and 0.5mM palmitate, 0.1mM DHA, 0.5mM palmitate plus 0.1mM DHA, or
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no FA for 96 hours, and fresh media was provided every 48 hours. For insulin-stimulation
experiments, myotubes were washed once with PBS and treated with 100nM insulin in DMEM
for 15 minutes.
Image capture and cell size. Images from myotubes that were treated for 48 and 96 hours were
visualized at x20 magnification using an inverted light microscope (Nikon) and captured with a
Spot RT camera and Spot Software (Diagnostic Instruments). Myotube diameter was measured
from randomly selected microscope fields from three different wells (35 mm) of control and
treated conditions (12 wells total per time-point) using Image J software (37). Six diameters were
measured per myotube, and ten myotubes were measured per well, except in the case of
palmitate-treated cells, where if ten myotubes were not present, all of the remaining myotubes
were measured.
Evaluation of phosphorylated and total proteins. Cells were harvested by scraping in 1 x SDS
sample buffer (1% SDS, 6 mg/mL EDTA, 0.06 M Tris (hydroxymethyl) aminomethane (pH 6.8),
2 mg/mL bromophenol blue, 15% glycerol, and 5% β-mercaptoethanol). Protein concentrations
were quantified in duplicate using an RC DC protein assay and averaged for determination of
Western blot loading volumes. Aliquots (30 μg/ml) of harvested C2C12 cells were resolved by
10%, 3-8%, or 4-12% SDS-PAGE using pre-cast gels. Control and treated cells were loaded on
the same gel to account for possible variations between blots, as well as a standard molecular
weight marker to verify protein sizes. Proteins were transferred to a nitrocellulose membrane
and stained with Ponceau S red to confirm transfer. Membranes were probed with primary
antibodies against phosphorylated T172 for AMPKα, S79 for ACC, S636/639 for IRS-1, S473
for Akt, S21/9 for GSK3α/β, S240/244 for rpS6, or for total protein expression of PGC1α and
COX-IV. Membranes were then probed with anti-species conjugated horseradish peroxidase
secondary antibodies. Blots were developed as described below. Where appropriate,
membranes were stripped with 1X ReBlot Plus Strong Solution and probed with antibodies
against total protein expression of AMPKα, ACC, Akt, GSK3β, β-tubulin, and GAPDH. Signals
for GAPDH were developed by enhanced chemiluminescence and for all other proteins by
advanced ECL, and bands were visualized by exposing the membranes X-ray film. Digital
records of the films were captured with a Kodak 290 camera, and bands were quantified as
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optical density x band area by a one-dimensional image analysis system (Eastman Kodak) and
expressed in arbitrary units normalized relative to the loading control.
Oil red O stain. Oil Red O (ORO) staining was performed as a visual marker to evaluate the
effects of FA treatments on intramyocellular lipid content after 48 and 96 hours (15). Cells were
grown, differentiated, and treated with FA as previously described. A 5g/L ORO stock solution
was prepared in a 3:2 ratio of 99% triethyl phosphate to distilled water. For staining, the stock
solution was diluted to a 36% ORO/TEP working solution then filtered three times by passing
through a syringe with a 0.45 micron filter tip. Culture dishes were washed three times with PBS
and myotubes fixed with 10% formalin then washed with distilled water and stained with 36%
ORO/TEP. Stained myotubes were rinsed with distilled water and visualized. Intramyocellular
lipid content was quantified by measuring fluorescence (excitation 485nm, emission 530nm) of
the stained lipids, and values were normalized to protein content per well, which was determined
using a commercially available kit.
Citrate Synthase Activity. To evaluate the effects of FA treatments on mitochondria oxidative
metabolism after 96 hours, the activity level of citrate synthase (CS) was evaluated using an
assay kit according to the manufacturer’s instructions. Cells were grown, differentiated, and
treated with FA as previously described. Cells were lysed in 200 μL of CelLytic M Reagent,
centrifuged at 12,000 x g, and the supernatant transferred to a chilled test tube. Protein content
was determined as described previously. The sample reaction mixture was prepared with the
appropriate volumes of 1 x Assay Buffer, 30 mM Acetyl CoA Solution, and 10 mM DTNB
solution and added to 10μL of sample in a 96-well plate. The spectrophotometer was set at 412
nm, and absorbances were measured at 0, 1, and 2 minutes. After determining the baseline
absorbance of the reaction mixture for 2 minutes, 10 mM Oxaloacetate Solution was added to the
reaction, and the absorbance was read for another 2 minutes to determine total CS activity. All
samples were evaluated in triplicate. CS activity for each sample was calculated per
manufacturer instructions and was normalized to protein content. A CS positive control was
included for each experiment.
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Statistical Analyses. All results represent the mean percent change ± standard error for a
minimum of three cell culture experiments (n=3) in triplicate, with exception to insulinstimulation experiments which consists of two experiments (n=2) in triplicate. One-way
ANOVA with Tukey post-hoc analysis was used to evaluate differences for each variable
between treatments, and statistical significance was set at P ≤ 0.05. Analyses were conducted
using SPSS 12.0.1 software package.
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CHAPTER 4. RESULTS

Selection of fatty acid doses and treatment duration. To choose fatty acid concentrations and
time-points for study, dose- and time-response curves were generated to evaluate both myotube
morphology and levels of phosphorylated and total AMPK, since it was the primary protein of
interest. Dose-response curves (Figure 1) indicated that 0.75mM and 1.0mM palmitate
treatments and 1.0mM DHA had high phospho-to-total AMPK ratios; however, there were few
or no cells left on the plate after 24 hours with palmitate treatment in these concentrations, and
the idea with the DHA treatment was not to bombard the cells with DHA, but to add a small
amount of polyunsaturated fatty acids in comparison to the saturated fatty acids as done
previously (18, 21, 38, 39, 41). Therefore, we chose 0.5mM palmitate and 0.1mM DHA, as they
provided the next greatest phosphorylation of AMPK without loss of cellular integrity and gave a
polyunsaturated:saturated fatty acid ratio of 0.2, which is similar to previous studies using a ratio
of 0.25 (21).
To determine the duration of treatment, we evaluated the myotube morphology and size.
Since there were no apparent changes in morphology after 24 hours (Figure 2A), we focused on
48 and 96 hour time-points for measurement of myotube diameter (Figure 2B). Palmitate
treatment decreased myotube diameter by 25% (p=0.052) after 48 hours and over 90% (p<0.001)
after 96 hours versus control. However, DHA maintained myotube morphology and diameter;
adding DHA to the palmitate treatment increased myotube diameter by almost half (p=0.004)
after 48 hours and over 100% (p<0.001) after 96 hours versus palmitate alone. Because the most
dramatic change in myotube morphology and size without complete loss of palmitate cells
occurred at 96 hours, we chose this time-point to conduct subsequent measurements.
Furthermore, since a treatment effect on β-tubulin levels at timepoints longer than 24 hours was
observed, all subsequent western blot measures were normalized to GAPDH protein expression
because it did not demonstrate a time x treatment effect.
Palmitate-induced detriments to myotube morphology and size are attenuated by DHA. To
determine if maintenance of myotube morphology with DHA treatment was due to activation of
the AMPK pathway, we measured phosphorylation of AMPKα on Thr172, which is required for
its activation (40), and total AMPK protein expression (Figure 3A). Phospho-AMPKαThr172
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levels were not significantly different between treatments, but addition of DHA to the palmitate
treatment led to 106% higher (p=0.05) total AMPK levels than palmitate alone, which was
associated with a 5.7-fold increase (p=0.032) in the AMPK ratio in palmitate versus control
conditions.
To determine if the activation of AMPK with palmitate treatment was propagated
downstream, we examined its cytosolic target, acetyl Co-A carboxylase (ACC) (Figure 3B).
AMPK inhibits ACC through phosphorylation on Ser79, which reduces lipid synthesis and
allows for fatty acyl-CoA entry into the mitochondria (43). While all fatty acid treatments led to
increases in phospho-ACCSer79 levels, there were no significant changes between treatments or
versus control. These data are consistent with the phospho-AMPKαThr172 data (Figure 3A). The
total ACC levels mirrored its phosphorylated levels and were also no significantly different
between treatments; therefore, the ACC ratio was also similar between treatments (Figure 3B).
Palmitate treatment increases intramyocellular lipid content of myotubes. Since AMPK is
considered to be a regulator of lipid homeostasis in skeletal muscle (45), next we evaluated the
intramyocellular lipid content with different fatty acid treatments. Myotubes were stained with
Oil red O, which indicates the levels of all neutral lipids. There was a 400% (p<0.000) increase
in auto fluorescence of Oil red O stained myotubes with palmitate treatment when normalized to
average protein content per treatment. Intramyocellular lipid content returned to control levels in
DHA-palmitate co-treated myotube cultures (Figure 4).
DHA maintains protein abundance of oxidative markers in palmitate-treated myotubes. Since
AMPK is also known to activate transcription for long-term regulation of lipid homeostasis (20),
the total protein expression of its nuclear target, PGC1α, was measured. PGC1α is a
transcription factor responsible for expression of genes involved in oxidative metabolism.
Palmitate treatment decreased PGC1α protein expression by 69% versus control (p=0.4),
although the addition of DHA to the palmitate treatment completely attenuated this effect by
increasing its protein expression 165% (p=0.017) versus palmitate treatment alone (Figure 5A).
This suggests that DHA preserves oxidative metabolic capacity in palmitate-treated cells. To
determine if the improvement in PGC1α expression with DHA was matched downstream by an
increase in oxidative metabolism, we measured CS activity as a marker of the tricarboxylic acid
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cycle and COX-IV protein expression as an indicator of the of the electron transport chain. We
found disparate effects on these oxidative markers. CS activity demonstrated a small but
significant 3% increase (p<0.05) with palmitate treatment versus all other conditions, and
addition of DHA to palmitate had similar CS activity as control cells (Figure 5B). However,
palmitate treatment led to a 34% decrease (p=0.297) in COX-IV protein expression, while
addition of DHA returned COX-IV expression to control levels (Figure 5C).
DHA attenuates palmitate-induced detriments in the insulin signaling pathway. To determine
if changes in intramyocellular lipid content and markers of oxidative metabolism with DHA
treatment led to alterations in the insulin signaling pathway, the inhibitory serine
phosphorylation site of the insulin receptor substrate (IRS) 1 was examined. All fatty acid
treatments elevated p-IRS-1Ser636/639 by 2-3-fold, although these increases were not significant
from each other or control conditions (Figure 6). Because changes were noted in markers of
lipid content and oxidative metabolism with the different treatments, which were associated with
disparate effects on myotube morphology and size, investigation of insulin signaling was
continued further downstream of IRS-1 to examine activation of Akt, GSK3β, and rpS6. The
phosphorylation of Akt on Ser473 was measured because it is required for its activation (13), and
previous research has demonstrated it to be decreased with palmitate treatment in skeletal muscle
(18, 29, 33). Although not statistically significant, Akt phosphorylation and total protein were
decreased by at least one-third and phospho-GSK3β by almost half with palmitate treatment
versus control conditions, while addition of DHA completely attenuated these decreases (Figure
7A&B). Contrary to the Akt data, however, total GSK3β levels remained unchanged (Figure
7A&C). The effects of DHA on palmitate treatment continued all the way downstream to rpS6;
palmitate decreased phospho-rpS6Ser240/244 levels to approximately 25% of control, while addition
of DHA increased its activation by 7-fold (p=0.017) (Figure 8).
To observe the responsiveness of the signaling pathway, myotubes were stimulated with
100nM insulin for 15 minutes, a dose and time consistent with previous literature performing
immunoblotting (5) and chosen to elicit a maximal signaling response. Overall, DHA again
attenuated the decrements of palmitate treatment (Figure 9). Phospho-Akt was reduced by half
by palmitate treatment, although not statistically significant, and total Akt protein expression was
only ~25-45% of the other treatments (p<0.02). Activation of GSK3β was also decreased 5533

85% by palmitate (p<0.03). Addition of DHA attenuated all of these decreases to approximately
70% of control values (p<0.03). Together these data indicate a complete rescue of basal- and a
partial but significant attenuation of insulin-stimulated- signaling by adding the omega-3
polyunsaturated fatty acid DHA to the saturated fatty acid palmitate treatment.
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CHAPTER 5. DISCUSSION

The central aim of this thesis was to determine if long term administration of n-3 PUFAs
enhances FA oxidation and reduces intramyocellular lipid accumulation compared to palmitate
treatment through activation of the AMPK signaling pathway in skeletal muscle cell culture.
The central hypothesis was that long-term DHA treatment of C2C12 myotubes would activate the
AMPK pathway to improve oxidative capacity, reduce intramyocellular lipid content, and
enhance insulin signaling. The main finding of this thesis is that after 4 days of treatment in a
cell culture model of a high fatty acid environment, DHA attenuated the negative effects of
palmitate on myotube size and morphology, some measures of oxidative metabolism,
intramyocellular lipid content, and insulin signaling independently of AMPK activation. Overall
these data confirm previous findings (6, 8, 18, 21, 36, 39, 41) that omega-3 polyunsaturated fatty
acids have the ability to prevent detrimental effects of saturated fatty acids.
A most-striking initial finding of this research is that myotube morphology and size were
markedly and differentially altered by palmitate and DHA. Long-term treatment of cells with
palmitate altered the typical morphological properties of myotubes; after 2 days myotubes were
significantly smaller in diameter than with either control or DHA conditions, and after 4 days
very few myotubes remained and most cells lost adherence to the plate. However, this effect was
completely attenuated by co-treatment with DHA, as this group demonstrated a 12% increase in
diameter even over control cells after 4 days.
To determine if the changes in myotube morphology were associated with changes in protein
expression and activation of signaling proteins involved in lipid metabolism, we measured
AMPK phosphorylation and total protein expression. Contrary to our hypothesis, DHA does not
appear to exert its positive effects through activation of AMPK since all fatty acid treatments led
to non-significant 2-3-fold increases in phosphorylated AMPK. However, there was a significant
difference in the AMPK ratio between treatments, which was due to decreased total AMPK
levels in palmitate-treated cells. The total AMPK data are supported by previous findings that
total AMPKα protein levels were decreased by approximately 60% after 5 months of high fat
feeding in rodents. However, phospho-AMPKThr172 levels were also decreased (22), which is
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contrary to our data and could possibly reflect the differences between animal and cell culture
models.
The high AMPK ratio in the palmitate treated cells indicates that most of the remaining total
AMPK present in the cells was activated. Given the morphology of the cells treated with
palmitate, it is most-likely that the myotubes were undergoing apoptosis and/or death and were
trying to produce energy by activating the master energetic regulator that stimulates ATPproducing processes (44). While cell death was not measured, our lab has previously
demonstrated that 0.75mM palmitate treatment of myotubes for 16 hours lead to a 7-fold
increase in DNA fragmentation versus control-treated cells (29), and the activation of AMPK via
AICAR treatment in differentiating C2C12 myoblasts led to increased DNA fragmentation and
caspase-3 cleavage (46). These data along with the morphological characteristics of the cells
suggest that the palmitate-treated cells were undergoing apoptosis.
Moreover, addition of DHA to the palmitate treated cells maintained the AMPK phospho:total
ratio near control levels, and the morphological and cell size data of these cells was similar to
control-treated myotubes. Together these findings support that DHA did not differentially
increase AMPK phosphorylation but was able to maintain the AMPK ratio through attenuation
of the decrease in total AMPK and possibly contribute to the attenuation of cellular atrophy and
death. Our phospho-AMPK data may be different from the findings of Liu et al. (22) because we
were examining a more extreme model of atrophy/cell death than their animal model.
The cytosolic downstream target of AMPK, ACC, similarly demonstrated nonsignificant 2-4fold increases in phosphorylation but did not display decreased total ACC levels, leading to
similar ratios of phosphorylated to total ACC in all conditions. These data suggest that ACCmediated fatty acid oxidation was not different between treatments and that lipid synthesis may
also be similar because two of the primary cellular metabolic fates of long chain fatty acyl Co-A
molecules are β-oxidation or conversion to diacylglycerol and triacylglycerol for storage (35).
To determine if the fatty acid treatments led to differential changes in lipid storage,
intramyocellular lipid content was examined. Because activation of AMPK decreases expression
of genes involved in lipid synthesis (3), an increase in the phosphorylated:total AMPK ratio
suggests that intramyocellular lipid content should be decreased with palmitate treatment. This
is not what the data indicated, as intramyocellular lipid content was substantially increased in the
palmitate-treated cells versus the other conditions, which is consistent with our hypothesis.
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Pimenta et al. (30) also observed 2.5-to-3-fold increases in phosphorylation of AMPK and ACC
after palmitate treatment, which was associated with approximately 3-fold increases in
intramyocellular lipids. Moreover, apart from measurements of AMPK activation, the conditions
of obesity (24, 31) and high fat-feeding (10, 38) are shown to increase intramyocellular lipid
content. These data indicate that although DHA was able to reduce accumulation of
intramyocellular lipids when added to the palmitate treatment, this alteration was not through
activation of the AMPK pathway. It is possible that the reduced intramyocellular lipid content in
the control and both DHA treatments was due to an increase in lipid oxidation versus palmitate
conditions, resulting in lower net lipid content versus palmitate-treated cells.
We hypothesized that addition of DHA to the palmitate treatment increases the ability of the
cell to deal with the influx of fatty acids by improving oxidative metabolism; therefore, the
transcription factor PGC1α was examined. PGC1α is located in the nucleus and promotes
expression of genes involved in oxidative metabolism (2, 16, 17, 27). Addition of DHA to the
palmitate treatment maintained PGC1α near control levels, which indeed suggests that DHA may
maintain palmitate-induced decreases in oxidative metabolism to improve utilization of
intramyocellular lipids and attenuate cellular atrophy and/or death. In line with this, there are
data to suggest a relationship between PGC1α expression level and cell size. Sandri et al. (34)
demonstrated a sharp decrease in PGC1α mRNA expression in diabetes-induced atrophied
muscle, which they suggested may be triggered by insulin resistance. They also showed that
maintenance of PGC1α levels conferred protection from muscle atrophy by inhibiting
transcription of atrophy-related genes, which they noted may be an indirect effect of a PGC1αmediated increase in mitochondrial content or β-oxidative metabolism (34). Our data support
these findings and suggest that maintenance of PGC1α and resulting differences in oxidative
metabolism may contribute to cell size and morphology in a high fat environment.
One consideration that must be made when interpreting the results of this study deals with the
apparent uncoupling between the AMPK ratio and the phosphorylation of ACC and protein
expression of PGC1α, which would both be expected to increase with an increase in the AMPK
ratio. The data of Suzuki et al. (40) may partially explain the disparate effects on the cytosolic
and nuclear targets of AMPK in our study. They demonstrated that phosphorylation of Thr172
on the α2 subunit is critical for activity of AMPK and that the regulatory β subunit determines its
subcellular localization. Upon leptin stimulation of C2C12 myoblasts, the AMPKα2/β1 complex
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remained in the cytosol while the α2/β2 complex translocated to the nucleus after 1 hour,
returned to the cytosol after 3 hours, and localized to both the nucleus and cytosol after 6 hours
(40). Since both nuclear and cytosolic targets of AMPK rely on phosphorylation of α2 but were
not affected similarly in our study, it is unlikely that a decrease in α2 could be solely responsible
for the decrease in PGC1α expression. It is possible that α1 levels could be decreased with
palmitate treatment, as the antibody for total AMPK targeted both α subtypes, but this is also
unlikely because α1 does not translocate to the nucleus (40) which is where the most detrimental
effects occurred to AMPK substrates with palmitate treatment. Therefore, palmitate treatment
could have altered both protein expression of the AMPK α2 and β2 subunits, leading to a
decrease in nuclear translocation of the complex and thus activation of transcription factors in the
nucleus. This would not necessarily affect phosphorylation of ACC, as the β1 subunit is
primarily responsible for localizing the complex to the cytosol, and given the long time-period,
the biphasic response of the α2/β2 complex would localize some of the remaining α2/β2 to the
cytosol to phosphorylate ACC. Further examination of the effects of FA on the β subunits are
needed to clarify this possibility.
To determine if markers of oxidative metabolism were maintained similarly to PGC1α
content by addition of DHA to palmitate treatment, the activity of CS and protein expression of
COX-IV were examined as markers of the tricarboxylic acid cycle and electron transport chain,
respectively. Contrary to our hypothesis, DHA did not increase CS activity either alone or with
palmitate treatment. Conversely, there was a small increase in CS activity with the palmitate
treatment, although most-likely not enough to translate to a physiologically-significant increase
in oxidative metabolism. This finding does go along with previous data demonstrating an
increase in CS activity in skeletal muscle after high fat feeding (42) and in the muscle of obese
animals (12). Ultimately, however, these data indicate that DHA did not rescue myotube
morphology by increasing enzyme activity of the initial step of the tricarboxylic acid cycle.
Alternatively, DHA did maintain COX-IV protein levels versus palmitate treatment alone. These
data support the idea that maintenance of PGC1α also maintains mitochondrial content in the
myotubes (34), which would result in preservation of oxidative enzyme protein content instead
of necessarily increasing enzyme activity to maintain oxidative capacity and ultimately myotube
morphology.
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Furthermore, Muoio and colleagues (16) found that high-fat-induced insulin resistance in
animals was associated with decreased expression of PGC1α and accumulation of intramuscular
acylcarnitines (from β-oxidation), while PGC1α overexpression in myocytes favored formation
of CO2 (complete fatty acid oxidation). They suggest that nutrient oversupply leads to an
increase in lipid oxidation where the flux of β-oxidative by-products overcomes the capacity of
the tricarboxylic acid cycle, resulting in incomplete fatty acid oxidation and accumulation of βoxidative intermediates that may contribute to mitochondrial malfunction (16). Considering
these findings, palmitate treatment may trigger a compensatory increase in CS activity as an
attempt to improve complete lipid oxidation in light of increased β-oxidative flux without
concomitant enhancement of downstream oxidative metabolism (i.e. COX-IV protein
abundance) due to decreased PGC1α expression. This is further supported by the finding that
DHA maintained PGC1α and attenuated all of these changes when added to palmitate treatment.
Muoio’s group demonstrated that the decrease in PGC1α expression in their high-fat-fed
animals was associated with insulin resistance (16), and Sandri et al. noted that diabetes-related
muscle atrophy may be triggered by insulin resistance (34). Moreover, there is a plethora of data
showing that saturated fatty acids are detrimental to skeletal muscle (19) and contribute to the
formation of insulin resistance (19, 25), while exposure to unsaturated fatty acids prevents,
attenuates, or reverses insulin resistance induced by saturated fatty acids and overnutrition (1, 4,
8, 19, 23, 25, 28, 32, 38, 39). Therefore, another aim of this thesis was to determine if DHA
could attenuate the negative effects of palmitate on the insulin signaling pathway in this cell
culture model of a high-fat environment. We examined phosphorylation of IRS-1 on serine
636/639, which is inhibitory to the protein We examined phosphorylation of IRS-1 on serine
636/639, which is inhibitory to the protein {Morino, 2005 #137}, and found that all fatty acid
treatments led to 2-3-fold increases in phosphorylation, but without significant differences
between treatments or compared to control. Since this measure did not offer much insight into
the sensitivity of the insulin signaling pathway, we continued downstream of IRS-1 and
measured protein expression and activation of three proteins in the insulin signaling pathway,
protein kinase B (Akt), glycogen synthase kinase (GSK) 3β, and ribosomal protein S6 (rpS6).
Akt is a downstream substrate of IRS-1 that can directly inhibit GSK3β, removing its inhibition
of glycogen synthase, as well as indirectly activate rpS6 and promote synthesis of proteins
involved in cell cycle progression (13). We also wanted to assess the responsiveness of the
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insulin signaling pathway after treatment with the different fatty acids but did not have means to
perform radioisotopic labeling for glucose uptake or glycogen synthesis as functional outcome
data; therefore, Akt and GSK3β activation and total protein levels after insulin stimulation were
measured.
The palmitate-induced decrease in basal and insulin-stimulated Akt activation is consistent
with previous research from our lab that demonstrated over 30% decreases in phospho-AktSer473
and total Akt after treatment of myotubes with 0.75mM palmitate for 16 hours followed by 10
minutes of serum-stimulation (29). In addition, another group found an approximate 40%
decrease in phospho-AktSer473 upon insulin stimulation after 24 hours of palmitate treatment but
not after treatment with oleate (a monounsaturated fatty acid) in cultured myotubes (33),
highlighting the differential effects of unsaturated and saturated fatty acids on the insulin
signaling pathway. More specifically to omega-3 polyunsaturated fatty acids, previous data
demonstrated an enhancement of insulin signaling through Akt-mTOR-S6K-4EBP1 in steers fed
with long-chain omega-3 fatty acids (9), and our finding of increased rpS6 phosphorylation with
addition of DHA to the palmitate treatment expands this finding, as it is a substrate of S6K.
Together these data support the idea that the saturated fatty acid palmitate blunted growth and
markers of oxidative metabolism, increased intramyocellular lipid content, and caused
unresponsiveness to very high concentrations of insulin. However, the omega-3 polyunsaturated
fatty acid DHA restored insulin responsiveness and cellular growth, as evidenced by the fact that
addition of DHA attenuated the palmitate-induced changes in myotube morphology and size,
intramyocellular lipid content, and PGC1α and COX-IV protein abundance, which was
associated with improved basal and insulin-stimulated signaling. While it is not a completely
novel finding that omega-3 fatty acids improve insulin signaling in skeletal muscle, as Storlien
and colleagues demonstrated a positive effect of fish oil on systemic insulin sensitivity in 1987
(39), these data supports a novel theory for how long-chain omega-3 fatty acids may improve
insulin signaling in skeletal muscle in a high fat environment. One of the most significant
findings was that DHA maintained PGC1α protein expression, and it is warranted to continue
investigating whether this promotes oxidative metabolism and preserves mitochondrial mass and
quality to prevent insulin resistance and cellular atrophy.
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Limitations and Future Directives
One limitation of this study is the lack of oxidative metabolic markers compared to the amount
necessary to draw solid conclusions. Inclusion of a single transcription factor and only two
markers in the entire oxidative pathway provides limited data with which to draw conclusions
regarding the oxidative capacity of the cells after fatty acid treatment. This is especially
significant in this data because we saw disparate effects on our oxidative markers with a slight
palmitate-induced increase in CS activity and no change with addition of DHA, but decreased
palmitate-induced protein abundance of PGC1α and COX-IV, which was reversed with DHA.
To strengthen these data, further examination of oxidative markers is required. These
measurements should focus on both clarifying the differential effects on enzyme activity versus
protein expression and identifying the functional outcome of these changes (i.e. lipid oxidation
rates).
CS protein expression and COX activity should be measured to complement the measurement
of its activity and protein abundance, respectively. The activity and protein expression of
another tricarboxylic acid cycle enzyme, such as succinate dehydrogenase, and electron transport
chain component, such as COX-I, could also be examined to provide a more comprehensive
evaluation of the capacity of the tricarboxylic acid cycle and electron transport chain.
To identify if the maintenance of PGC1α by DHA treatment alters “functional” outcomes of
oxidative metabolism, mitochondrial content should be quantified to confirm that the protein
expression of PGC1α correlates to the mitochondrial content. This would nicely complement the
markers of mitochondrial quality (CS and cytochrome c oxidase protein expressions and
activities) to indicate overall mitochondrial capacity. Furthermore, lipid oxidation should also be
measured as a functional outcome. The argument that fatty acid treatments increase lipid
oxidation but without matching of tricarboxylic acid cycle and electron transport chain activity
(26) suggests that measuring both incomplete and complete lipid oxidation is required. Previous
data indicate that this can be accomplished by evaluating lipid incorporation into acid soluble
metabolites (incomplete oxidation) and carbon dioxide (complete oxidation) (7, 16). Together
these measurements would allow for a more complete examination of the oxidative metabolic
capacity of myotubes after treatment with saturated and polyunsaturated fatty acids and allow for
a more solid argument to be made with respect to their differential effects.
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Along the same lines as functional outcomes for oxidative metabolism, measuring more
functional markers of insulin signaling would provide a clearer idea of the actual significance of
the basal and insulin-stimulated Akt and GSK3β protein expressions. While there are data that
demonstrate omega-3-related improvements in systemic insulin sensitivity in animal (8, 38, 39)
and human models (11) of insulin resistance, we cannot assume that these changes in insulin
signaling in cell culture models holds equal value. Therefore, a functional measurement of
glucose uptake, glycogen synthesis, and/or protein synthesis rate would strengthen these data.
As previously discussed, it is possible that palmitate treatment not only reduced AMPKα2
protein expression, but also protein expression of the β2 subunit. Since the α2/β2 subunit
translocates to the nucleus to activate and enhance protein expression of PGC1α (14, 20, 40), the
decrease of its abundance in the palmitate-treated cells could be due to loss of β2 expression, as
well. This possibility should be examined by measuring the total protein abundances of the β1
and β2 subunits by Western blotting. The data regarding phosphorylation (activation) of PGC1α
by AMPK is limited (14), and when good antibodies for these phosphorylation sites become
commercially available, Western blotting could also be used to further examine if the
phosphorylation of PGC1α (indicating its activity) is altered similarly to its protein expression
with the different fatty acid treatments.
Lastly, it is possible that the methods used in the cell culture model itself could be a limitation
to this study. Recently Muoio’s group published data suggesting that cell culture experiments
examining the effects of fatty acid treatments on metabolic makers should include supplemental
carnitine in the culture culture media (17). Carnitine is necessary for the formation of long chain
acyl-carnitines from fatty acyl-CoA by carnitine palmitoyl transferase-1 in order to enter the
mitochondria for β-oxidation (35). Since carnitine is synthesized in the liver, storage of carnitine
in cultured skeletal muscles is very low which can restrict β-oxidation (17). Therefore, future
studies examining the effects of saturated versus polyunsaturated fatty acids should include
supplemental carnitine in the media in order to allow for physiologically normal β-oxidation to
occur. This would ensure that any changes in β-oxidation with the different fatty acids would
not be simply due to a decrease in necessary precursors for lipid oxidation.
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Figure Legends
Figure 1. Dose-response curves for activation of AMPK following palmitate and cis-4, 7, 10, 13,
16, 19-docosahexaenoic acid (DHA) treatments. Cells were incubated in medium containing 2%
fetal calf serum, 2% bovine serum albumin, and the indicated fatty acid concentrations for 24
hours. Cells were harvested by scraping in 1X SDS-containing sample buffer, and samples were
analyzed for phosphorylation of AMPK on Thr172 and total AMPKα and were normalized to βtubulin. Representative Western blots are shown.
Figure 2. Myotube morphology and diameter are differentially altered with palmitate versus
DHA treatment. Cells were incubated in medium containing 2% fetal calf serum, 2% bovine
serum albumin, and either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16,
19-docosahexaenoic acid (DHA), or 0.1mM DHA plus 0.5mM palmitate for 24, 48, or 96 hours.
Fresh media was supplied after 48 hours. A) Images of myotubes after indicated treatment
durations were collected via computer-integrated camera connected to a microscope at x10. B)
Myotube diameter of treated cells. Six diameters per myotube from ~10 myotubes (per culture)
from three wells per treatment condition that were treated for 48 and 96 hours with palmitate,
DHA, DHA+palmitate, or no fatty acids. *Denotes p≤0.05 versus other 48h treatment conditions;
§

Denotes p<0.00 versus other 96h treatment conditions; **Denotes p<0.05 versus 96h control

conditions.
Figure 3. DHA attenuates the reduced total AMPKα protein expression and the increased
AMPK ratio observed with palmitate treatment. Cells were incubated in medium containing 2%
fetal calf serum, 2% bovine serum albumin, and either no fatty acids (Control), 0.5mM palmitate,
0.1mM DHA, or 0.1mM cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid (DHA) plus 0.5mM
palmitate for 96 hours with fresh media supplied after 48 hours. Cells were harvested by scraping
in 1X SDS-containing sample buffer, and samples were analyzed for protein expression and
normalized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH) protein expression.
Representative Western blots are shown. A) Phosphorylation of AMPK on Thr172 was not
different between treatments, but co-treatment of DHA+Palmitate increased total AMPKα and
attenuated the increased AMPK ratio observed with palmitate treatment. B) No significant
differences were observed in phosphorylation of ACC on serine79, total ACC protein expression,
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or the ACC ratio. *Denotes p≤0.05 versus palmitate conditions for total AMPKα. §Denotes
p<0.05 versus all other conditions for the AMPK ratio.
Figure 4. Palmitate treatment increases intramyocellular lipid content. Cells were incubated in
medium containing 2% fetal calf serum, 2% bovine serum albumin, and either no fatty acids
(Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid (DHA), or
0.1mM DHA plus 0.5mM palmitate for 96 hours with fresh media supplied after 48 hours. After
treatment, cells were treated with a 36% Oil red O/triethyl phosphate solution that stains all
neutral intramyocellular lipids and autofluoresces. Fluorescence was measured (excitation
485nm, emission 530nm) and normalized to average protein content per treatment. *Denotes
p<0.0001 versus all other conditions.
Figure 5. DHA maintains markers of oxidative metabolism in palmitate-treated cells. Cells were
incubated in medium containing 2% fetal calf serum, 2% bovine serum albumin, and either no
fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid
(DHA), or 0.1mM DHA plus 0.5mM palmitate for 96 hours with fresh media supplied after 48
hours. For analysis of protein expression, cells were harvested by scraping in 1X SDS-containing
sample buffer and subjected to Western blotting. Expression was normalized to
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) protein expression. Representative
Western blots are shown. A) Protein expression of peroxisome proliferator-activated receptor
gamma coactivator 1α (PGC1α) is increased by adding DHA to palmitate treatment. *Denotes
p<0.05 versus palmitate condition. B) Citrate synthase (CS) activity. Treated cells were lysed
with CellLytic M and mixed with acetyl coenzyme A, oxaloacetic acid, and 5-thio-2nitrobenzioc acid to spectrophotometrically measure CS activity by reading absorbance at
412nm. §Denotes p<0.05 versus all other conditions. C) Cytochrome c oxidase subunit IV (COXIV) protein expression is not significantly altered with different fatty acid treatments.
Figure 6. Phosphorylation of IRS-1 is not different between palmitate and DHA treatments.
Cells were incubated in medium containing 2% fetal calf serum, 2% bovine serum albumin, and
either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16, 19docosahexaenoic acid (DHA), or 0.1mM DHA plus 0.5mM palmitate for 96 hours with fresh
media supplied after 48 hours. Cells were harvested by scraping in 1X SDS-containing sample
buffer and analyzed for protein expression of IRS-1 phosphorylation on serine636/639 and
48

normalized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH) protein expression.
Representative Western blots are shown.
Figure 7. DHA treatment attenuates the palmitate-induced decrease in basal insulin signaling.
Cells were incubated in medium containing 2% fetal calf serum, 2% bovine serum albumin, and
either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10, 13, 16, 19docosahexaenoic acid (DHA), or 0.1mM DHA plus 0.5mM palmitate for 96 hours with fresh
media supplied after 48 hours. Cells were harvested by scraping in 1X SDS-containing sample
buffer and analyzed for protein expression Akt and GSK3β normalized to glyceraldehydes-3phosphate dehydrogenase (GAPDH) protein expression. A) Representative Western blots for
phospho-AktSer473, phospho-GSK3βSer9, total Akt and GSK3β. B) Basal phospho- and total Akt
levels were not statistically different between treatments. C) Addition of DHA attenuated the
decrease in basal phosphorylation of GSK3βSer9 seen with palmitate treatment, but total GSK3β
expression was unchanged. *Denotes p<0.05 versus DHA conditions.
Figure 8. DHA treatment attenuates the palmitate-induced decrease in basal activation of
ribosomal protein S6 (rpS6). Cells were incubated in medium containing 2% fetal calf serum, 2%
bovine serum albumin, and either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7, 10,
13, 16, 19-docosahexaenoic acid (DHA), or 0.1mM DHA plus 0.5mM palmitate for 96 hours
with fresh media supplied after 48 hours. Cells were harvested by scraping in 1X SDScontaining sample buffer and analyzed for phosphorylation of rpS6 on Ser240/244 and
normalized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH) protein expression.
Representative Western blots are shown. *Denotes p<0.05 versus palmitate condition.
Figure 9. DHA treatment attenuates the palmitate-induced decrease in insulin-stimulated
activation of signaling proteins. Cells were incubated in medium containing 2% fetal calf serum,
2% bovine serum albumin, and either no fatty acids (Control), 0.5mM palmitate, 0.1mM cis-4, 7,
10, 13, 16, 19-docosahexaenoic acid (DHA), or 0.1mM DHA plus 0.5mM palmitate for 96
hours with fresh media supplied after 48 hours. Cells were stimulated with 100nM insulin for 15
minutes then harvested by scraping in 1X SDS-containing sample buffer and analyzed for
protein expression Akt and GSK3β normalized to glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) protein expression. A) Representative Western blots for phospho-AktSer473, phosphoGSK3βSer9, total Akt and GSK3β with insulin stimulation. B) DHA attenuates the palmitate49

induced decrease in insulin-stimulated total Akt protein expression. *Denotes p<0.05 versus all
other conditions. C) DHA attenuates the palmitate-induced decrease in insulin-stimulated
phosphorylation of GSK3βSer9 and the ratio of phospho- to total GSK3β. †Denotes p<0.05
versus all other conditions for pGSK3β. §Denotes p<0.05 versus all other conditions for the GSK
ratio.
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